INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers reported 3-year outcomes for both anti-amyloid drugs, lecanemab (Leqembi) and ...

Please provide your email address to receive an email when new articles are posted on . “It was great to see this real-world evidence in open-label extension studies, and I expect that over time we’ll ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

NA-831 is the only drug to date that has halted Alzheimer’s disease progression. Combining it with existing drugs like Donanemab could optimize therapeutic efficacy and reduce serious side effects.” — ...

A new Optum report highlighting upcoming medications in the drug pipeline is meant as a heads-up for payers as they track developments with a couple of therapies for Alzheimer's disease – lecanemab ...

AN Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

Donanemab—one of the two breakthrough therapies hailed globally for showing promising results in treating Alzheimer's disease—has been approved by India's apex drug regulator, and its maker Eli Lilly ...

Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) ...